IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF JUAN PEREZ-VILLAR, ET AL

FOR: IDENTIFICATION AND CLONING OF A FULL-LENGTH

HUMAN CLNK-RELATED GENE, MIST (MAST CELL

IMMUNORECPTOR SIGNAL TRANSDUCER)

APPLICATION NO: 09/966955

PATENT NO: 7241590

ART UNIT: 1646

CONFIRMATION NO: 4833

APPLICATION DATE: 09/28/2001

PATENT GRANT DATE: 10/JUL/2007

EXAMINER: MERTZ, PREMA MARIA

USPTO CUSTOMER NO: 23914

TRANSMITTED VIA EFS-WEB

Certificate of Corrections Branch Commissioner for Patents PO BOX 1450 Alexandria. VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR USPTO MISTAKE (37 C.F.R. §1.322) AND APPLICANT'S MISTAKE (37 C.F.R. §1.323)

Sir:

The patentees through their agent hereby respectfully request that a certificate of correction be issued to correct printing errors in accordance with the attached Certificate of Correction Form 1050.

The requested corrections for mistakes are clerical or typographical in nature and do not involve such changes in the patent as would constitute new matter or would require re-examination.

Pursuant to 37 C.F.R. §1.322, patentees request that a certificate of correction enclosed herewith be issued for mistakes by the Patent and Trademark Office as stated below.

Column (54) Title is incorrect.

Title should read:

"POLYNUCLEOTIDES ENCODING HUMAN CLNK-RELATED POLYPEPTIDE, MIST (MAST CELL IMMUNORECEPTOR SIGNAL TRANSDUCER)"

See Office Action Reply mailed September 1, 2006.

D0029 NP

What is Claimed is:

Col. 95, Claim 18, line 44 and 45

Substitute "48" with "443"

Claim 18 should now read:

"An isolated polynucleotide which represents the complete complementary sequence of either an isolated polynucleotide encoding a polypeptide comprising amino acids 1 to 443 of SEQ ID NO:2, or an isolated polynucleotide encoding a polypeptide comprising amino acids 2 to 443 of SEQ ID NO:2."

See Office Action Reply mailed September 1, 2006 regarding Claim 52 as well as 312 Amendment filed on January 4, 2007 regarding Claim 52.

Col. 95, Claim 19, line 48 Substitute "48" with "443"

Claim 19 should now read:

"An isolated polynucleotide encoding a polypeptide comprising amino acids 83 to 443 of SEQ ID NO:2, and wherein said polypeptide binds to Grb2, Vav, Lat, c-Cbl, or SLP-76."

See Office Action Reply mailed September 1, 2006 regarding Claim 53 as well as 312 Amendment filed on January 4, 2007 regarding Claim 53.

Col. 96, Claim 25, line 17
Substitute "48" with "443"
Claim 25 should now read:

"An isolated polynucleotide encoding a polypeptide comprising amino acids 320 to 443 of SEQ ID NO:2, and wherein said polypeptide binds to Grb2, Vav, Lat, c-Cbl, or SLP-76."

See Office Action Reply mailed September 1, 2006 regarding Claim 62 as well as 312 Amendment filed on January 4, 2007 regarding Claim 62.

Pursuant to 37 C.F.R. §1.323, patentees request that a certificate of correction enclosed herewith be issued for mistakes by Applicant as stated below.

Col. 96, claim 28, line 28

Substitute "consisting of" with "consists"

Claim 28 should now read:

"The isolated polynucleotide of Claim 27, wherein said polynucleotide consists of nucleotides 1289 to 1540 of SEQ ID NO:1."

Please send the certificate to the address registered with customer number 23914. The assignment on the above patent was recorded on February 19, 2002 and can be found on Reel 012636, Frame 0658 (9 pages) to Assignee, Bristol-Myers Squibb Company.

Please charge the fee set forth in §1.20(a) of \$100.00 and any additional fees to Deposit Account No. 19-3880 of the undersigned. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Stephen C. D'Amico Agent for Applicant Reg. No. 46,652

Phone: 609-252-5289 Date: 8-7-07 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page	1	of	つ

PATENT NO. : 7241590

APPLICATION NO.: 09/966955

ISSUE DATE : 10/JUL/2007

INVENTOR(S) : pepez VIII

PEREZ-VILLAR JUAN J, CHANG HAN, YANG WEN-PIN, WU YULI, WHITNEY GENA S.,

KANNER STEVEN B

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column (54) Title is incorrect.

Title should read:

" POLYNUCLEOTIDES ENCODING HUMAN CLNK-RELATED POLYPEPTIDE, MIST (MAST CELL IMMUNORECEPTOR SIGNAL TRANSDUCER)"

What is Claimed is:

Col. 95, Claim 18, line 44 and 45 Substitute "48" with "443"

Claim 18 should now read:

"An isolated polynucleotide which represents the complete complementary sequence of either an isolated polynucleotide encoding a polypeptide comprising amino acids 1 to 443 of SEQ ID NO:2, or an isolated polynucleotide encoding a polypeptide comprising amino acids 2 to 443 of SEQ ID NO:2."

Col. 95, Claim 19, line 48 Substitute "48" with "443"

Claim 19 should now read:

"An isolated polynucleotide encoding a polypeptide comprising amino acids 83 to 443 of SEQ ID NO:2, and wherein said polypeptide binds to Grb2, Vav, Lat, c-Cbl, or SLP-76."

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO.

: 7241590

APPLICATION NO.: 09/966955

ISSUE DATE

: 10/JUL/2007

INVENTOR(S)

PEREZ-VILLAR JUAN J, CHANG HAN, YANG WEN-PIN, WU YULI, WHITNEY GENA S.,

KANNER STEVEN B

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 96, Claim 25, line 17 Substitute "48" with "443"

Claim 25 should now read:

"An isolated polynucleotide encoding a polypeptide comprising amino acids 320 to 443 of SEQ ID NO:2, and wherein said polypeptide binds to Grb2, Vav, Lat, c-Cbl, or SLP-76."

Col. 96, claim 28, line 28

Substitute "consisting of" with "consists"

Claim 28 should now read:

"The isolated polynucleotide of Claim 27, wherein said polynucleotide consists of nucleotides 1289 to 1540 of SEQ ID NO:1."

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princelon, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submilling the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.